These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 36228411)

  • 1. Design, synthesis, and evaluation of 4(1H)-quinolinone and urea derivatives as KRAS
    Cheng R; Lv X; Bu H; Xu Q; Wu J; Xie K; Tang J; Wang L; Zhuang J; Zhang Y; Zhang Y; Yan C; Lai Y
    Eur J Med Chem; 2022 Dec; 244():114808. PubMed ID: 36228411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.
    Rosell R; Jantus-Lewintre E; Cao P; Cai X; Xing B; Ito M; Gomez-Vazquez JL; Marco-Jordán M; Calabuig-Fariñas S; Cardona AF; Codony-Servat J; Gonzalez J; València-Clua K; Aguilar A; Pedraz-Valdunciel C; Dantes Z; Jain A; Chandan S; Molina-Vila MA; Arrieta O; Ferrero M; Camps C; González-Cao M
    Cell Commun Signal; 2024 Jun; 22(1):324. PubMed ID: 38867255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D-1553: A novel KRAS
    Shi Z; Weng J; Niu H; Yang H; Liu R; Weng Y; Zhu Q; Zhang Y; Tao L; Wang Z; Huh SJ; Jiang Y; Mei H; Dai X; Zhang L; Wang Y
    Cancer Sci; 2023 Jul; 114(7):2951-2960. PubMed ID: 37158138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
    Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
    Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents.
    Li L; Zhao H; Peng X; Liu J; Mai R; Chen J; Lin L; Chen T; Yan J; Shi J; Chen J
    Bioorg Med Chem; 2022 Oct; 71():116962. PubMed ID: 35987104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
    Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
    Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity.
    Zhao H; Li L; Liu J; Mai R; Chen J; Chen J
    Bioorg Chem; 2022 Apr; 121():105652. PubMed ID: 35158284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganoderma microsporum immunomodulatory protein combined with KRAS
    Hua WJ; Hwang WL; Yeh H; Lin ZH; Hsu WH; Lin TY
    Int J Biol Macromol; 2024 Feb; 259(Pt 2):129291. PubMed ID: 38211909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel coumarin-based KRAS-G12C inhibitors from virtual screening and Rational structural optimization.
    Shi JT; Hou SJ; Cheng L; Zhang HJ; Mu HX; Wang QS; Wang ZY; Chen SW
    Bioorg Chem; 2024 Jul; 148():107467. PubMed ID: 38772290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS Approach.
    Meng L; Chan EW; Ng C; Aimi J; Tran JC; Oh AJ; Merchant M; Purkey HE; Heffron TP; Kaur S; Xu K; Shi Z; He J
    Anal Chem; 2022 Sep; 94(37):12927-12933. PubMed ID: 36083155
    [No Abstract]   [Full Text] [Related]  

  • 11. Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors.
    Imaizumi T; Shimada I; Satake Y; Yamaki S; Koike T; Nigawara T; Kaneko O; Amano Y; Mori K; Yamanaka Y; Nakayama A; Nishizono Y; Shimazaki M; Nagashima T; Kuramoto K
    Bioorg Med Chem; 2024 Jan; 98():117581. PubMed ID: 38176113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-Humans PET Imaging of
    Li X; Ye J; Wang J; Quan Z; Li G; Ma W; Zhang M; Yang W; Wang J; Ma T; Kang F; Wang J
    J Nucl Med; 2023 Dec; 64(12):1880-1888. PubMed ID: 37827842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of KRAS
    Kitai H; Choi PH; Yang YC; Boyer JA; Whaley A; Pancholi P; Thant C; Reiter J; Chen K; Markov V; Taniguchi H; Yamaguchi R; Ebi H; Evans J; Jiang J; Lee B; Wildes D; de Stanchina E; Smith JAM; Singh M; Rosen N
    Nat Commun; 2024 Jul; 15(1):6076. PubMed ID: 39025835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRAS
    Lv Y; Yang Z; Chen Y; Ma X; Guo M; Zhang C; Jiang X; Wang C; Li Z; Tai Z; Wang X; Zhang S; Ma S; Qin C
    J Med Chem; 2024 Feb; 67(4):2487-2511. PubMed ID: 38316747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade.
    Nokin MJ; Mira A; Patrucco E; Ricciuti B; Cousin S; Soubeyran I; San José S; Peirone S; Caizzi L; Vietti Michelina S; Bourdon A; Wang X; Alvarez-Villanueva D; Martínez-Iniesta M; Vidal A; Rodrigues T; García-Macías C; Awad MM; Nadal E; Villanueva A; Italiano A; Cereda M; Santamaría D; Ambrogio C
    Nat Commun; 2024 Aug; 15(1):7554. PubMed ID: 39215000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS
    Hoshiyama H
    Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
    Chen Y; Liu QP; Xie H; Ding J
    Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
    Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS
    Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.